Xellia Pharmaceuticals, headquartered in Copenhagen and owned by Novo A/S, increased revenue for 2016 by 17% to 257.4 MUSD. Net Result was 18.7 MUSD, which is a significant improvement compared to Xellia’s negative result of 3.6 MUSD in 2015.
Xellia is specialized in providing important anti-infective treatments against serious and often life-threatening infections.
“We have especially expanded in the US, where we have generated more than 50% of our total sales.” says Carl-Åke Carlsson, CEO at Xellia.
”2016 has been a transformational year, developing a new production facility in Cleveland, USA, which we acquired in November 2015” Carl-Åke Carlsson continues. “In November 2016, we received notice from the FDA to allow packaging and distribution of drug products at the site. This puts us in a great position to increase sales further in the important US market over the coming years.”
Xellia supplies Active Pharmaceutical Ingredients for anti-infectives and also develops and manufactures injectable Finished Dosage Forms for treatment of infections. Both areas are growing and Carl-Åke Carlsson expects that expanding the production capacity in the US will significantly increase sales of injectable anti-infective products.
/Carl-Åke Carlsson, CEO
Xellia Financial Highlights, 2016 compared to 2015
Key figures (MUSD)
- Revenue: 257.4 (2016) 220.2 (2015)
- EBITDA: 63.6 (2016) 40.7 (2015)
- Operating profit (loss) EBIT: 29.5 (2016) 9.5 (2015)
- Net profit (loss): 18.7 (2016) (3.6) (2015)
- Total Assets: 645.2 (2016) 562.0 (2015)
- Total number of employees: 1,352 (2016) 1,176 (2015)